Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2016900034AAU2016900034A0 (en) | 2016-01-07 | Mutated truncated von willebrand factor | |
PCT/AU2017/050010WO2017117631A1 (en) | 2016-01-07 | 2017-01-06 | Mutated truncated von willebrand factor |
Publication Number | Publication Date |
---|---|
SG11201805497QAtrue SG11201805497QA (en) | 2018-07-30 |
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201912498YASG10201912498YA (en) | 2016-01-07 | 2017-01-06 | Mutated truncated von willebrand factor |
SG11201805497QASG11201805497QA (en) | 2016-01-07 | 2017-01-06 | Mutated truncated von willebrand factor |
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201912498YASG10201912498YA (en) | 2016-01-07 | 2017-01-06 | Mutated truncated von willebrand factor |
Country | Link |
---|---|
US (1) | US10806774B2 (en) |
EP (1) | EP3400002B1 (en) |
JP (1) | JP6851381B6 (en) |
KR (1) | KR20180094114A (en) |
CN (1) | CN108472338B (en) |
AU (1) | AU2017204955B2 (en) |
BR (1) | BR112018013861A2 (en) |
CA (1) | CA3010720A1 (en) |
DK (1) | DK3400002T3 (en) |
ES (1) | ES2909573T3 (en) |
MX (1) | MX2018008337A (en) |
RU (1) | RU2018128582A (en) |
SG (2) | SG10201912498YA (en) |
WO (1) | WO2017117631A1 (en) |
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201805494WA (en) | 2016-01-07 | 2018-07-30 | Csl Behring Recombinant Facility Ag | Mutated von willebrand factor |
WO2018087267A1 (en)* | 2016-11-11 | 2018-05-17 | Csl Behring Recombinant Facility Ag | Truncated von willebrand factor polypeptides for treating hemophilia |
CN110520150A (en) | 2016-12-02 | 2019-11-29 | 比奥维拉迪维治疗股份有限公司 | Use the method for chimeric coagulation factor therapies hemophilic arthosis |
PL3641800T3 (en)* | 2017-06-22 | 2024-03-18 | CSL Behring Lengnau AG | Modulation of fviii immunogenicity by truncated vwf |
CN113039200B (en)* | 2018-05-18 | 2023-07-25 | 郑州晟斯生物科技有限公司 | Improved FVIII fusion proteins and uses thereof |
AU2019270184B2 (en) | 2018-05-18 | 2025-05-22 | Bioverativ Therapeutics Inc. | Methods of treating hemophilia A |
US10654911B1 (en) | 2019-04-02 | 2020-05-19 | Beijing Neoletix Biological Technology Co., Ltd. | Vector co-expressing truncated von Willebrand factor and factor VIII |
CN114072420B (en)* | 2019-07-04 | 2024-06-11 | 康诺贝林伦瑙有限公司 | Truncated Von Willebrand Factor (VWF) for increasing the in vitro stability of coagulation factor VIII |
CN110624105B (en)* | 2019-09-24 | 2021-06-11 | 苏州大学 | Sequences of structurally sensitive polypeptide antigens of von Willebrand factor |
US20220348637A1 (en)* | 2019-11-11 | 2022-11-03 | CSL Behring Lengnau AG | Polypeptides for inducing tolerance to factor viii |
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
US4970300A (en) | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
FR2673632A1 (en) | 1991-03-08 | 1992-09-11 | Lille Transfusion Sanguine | PROCESS FOR THE PREPARATION OF HUMAN VON WILLEBRAND FACTOR CONCENTRATE OF HIGH PURITY, SUITABLE FOR THERAPEUTIC USE |
AU6029594A (en) | 1993-01-15 | 1994-08-15 | Enzon, Inc. | Factor viii - polymeric conjugates |
DE4435485C1 (en) | 1994-10-04 | 1996-03-21 | Immuno Ag | Process for obtaining high-purity von Willebrand factor |
JPH11501506A (en) | 1994-12-12 | 1999-02-09 | ベス イスラエル デアコネス メディカル センター | Chimeric cytokines and their use |
WO1997003193A1 (en) | 1995-07-11 | 1997-01-30 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered metal-binding properties |
SE9503380D0 (en) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
AU3202797A (en) | 1996-04-24 | 1997-11-12 | Regents Of The University Of Michigan, The | Inactivation resistant factor viii |
US20040092442A1 (en) | 1996-04-24 | 2004-05-13 | University Of Michigan | Inactivation resistant factor VIII |
US6593294B1 (en) | 1998-04-27 | 2003-07-15 | Opperbas Holding B.V. | Pharmaceutical composition comprising Factor VIII and neutral liposomes |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
EP1351986A2 (en) | 2001-01-12 | 2003-10-15 | The American National Red Cross | Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii |
JP4361786B2 (en) | 2001-06-14 | 2009-11-11 | ザ スクリプス リサーチ インスティチュート | Stabilized proteins with engineered disulfide bonds |
WO2003076567A2 (en) | 2002-03-05 | 2003-09-18 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
US8586538B2 (en) | 2002-04-29 | 2013-11-19 | Stichting Sanquin Bloedvoorziening | Method of treating a patient suffering from a bleeding disorder comprising administering an antibody against the A3-C1 of FVIII |
WO2004058800A2 (en) | 2002-12-23 | 2004-07-15 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
HUE058897T2 (en) | 2003-02-26 | 2022-09-28 | Nektar Therapeutics | Polymer-factor viii moiety conjugates |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
DK2298347T3 (en) | 2003-05-06 | 2016-01-11 | Biogen Hemophilia Inc | COAGULATION FACTOR CHEMICAL PROTEINS FOR TREATING A HEMOSTATIC DISORDER |
WO2005000892A2 (en) | 2003-06-12 | 2005-01-06 | Eli Lilly And Company | Glp-1 analog fusion plroteins |
BRPI0417916A (en) | 2003-12-31 | 2007-04-10 | Merck Patent Gmbh | fc-erythropoietin fusion protein with improved pharmacokinetics |
US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
BR122016022033B8 (en) | 2004-11-12 | 2021-05-25 | Bayer Healthcare Llc | isolated polypeptide conjugates showing factor viii procoagulant activity, their use and pharmaceutical composition |
DK1835938T3 (en) | 2004-12-27 | 2013-11-04 | Baxter Int | Polymer-von Willebrand factor conjugates |
AU2006233638A1 (en) | 2005-04-14 | 2006-10-19 | Csl Behring Gmbh | Modified coagulation Factor VIII with enhanced stability and its derivates |
EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
NZ572050A (en) | 2006-03-31 | 2011-09-30 | Baxter Int | Factor VIII conjugated to polyethylene glycol |
DK3896090T3 (en) | 2006-06-14 | 2022-03-21 | Csl Behring Gmbh | PROTEOLYTIC SPLIT FUSION PROTEIN INCLUDING A BLOOD COAGAGATION FACTOR |
JP5448839B2 (en) | 2006-12-22 | 2014-03-19 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | Modified clotting factor with long half-life in vivo |
CA2704234A1 (en)* | 2007-11-09 | 2009-05-14 | Baxter International Inc. | Modified recombinant factor viii and von willebrand factor and methods of use |
DK2865760T3 (en) | 2008-06-24 | 2018-01-15 | Csl Behring Gmbh | Factor VIII, Von Willebrand Factor or complexes thereof with extended in vivo half-life |
KR101874834B1 (en) | 2009-10-30 | 2018-07-05 | 알부메딕스 에이/에스 | Albumin variants |
US8759293B2 (en) | 2009-11-13 | 2014-06-24 | Grifols Therapeutics Inc. | von Willebrand factor (vWF)-containing preparations, and methods, kits, and uses related thereto |
KR20130070576A (en) | 2010-04-09 | 2013-06-27 | 노보자임스 바이오파마 디케이 에이/에스 | Albumin derivatives and variants |
EP2635598A1 (en) | 2010-11-01 | 2013-09-11 | Novozymes Biopharma DK A/S | Albumin variants |
CN104011072B (en) | 2011-05-05 | 2018-10-12 | 阿尔布梅迪克斯医疗有限公司 | albumin variants |
WO2013093760A2 (en)* | 2011-12-19 | 2013-06-27 | Grifols, S.A. | Compositions, methods, and kits for preparing sialylated recombinant proteins |
PL2804623T3 (en) | 2012-01-12 | 2020-03-31 | Bioverativ Therapeutics Inc. | Chimeric factor viii polypeptides and uses thereof |
WO2013120939A1 (en) | 2012-02-15 | 2013-08-22 | Csl Behring Gmbh | Von willebrand factor variants having improved factor viii binding affinity |
PL2825556T3 (en) | 2012-03-16 | 2018-10-31 | Albumedix A/S | Albumin variants |
EP2841451A1 (en) | 2012-04-24 | 2015-03-04 | Novo Nordisk A/S | Compounds suitable for treatment of haemophilia |
HUE047088T2 (en) | 2012-07-11 | 2020-04-28 | Bioverativ Therapeutics Inc | Factor viii complex with xten and von willebrand factor protein, and uses thereof |
JP6487328B2 (en) | 2012-11-08 | 2019-03-20 | アルブミディクス リミティド | Albumin variant |
CN105452289A (en) | 2013-06-12 | 2016-03-30 | 诺和诺德股份有限公司 | Compounds suitable for treatment of haemophilia |
ES2895798T3 (en)* | 2014-06-06 | 2022-02-22 | Octapharma Ag | Preparation comprising peptides of factor VIII and von Willebrand factor |
BR112016030950A2 (en) | 2014-07-02 | 2018-03-27 | Csl Ltd | modified factor viii binding polypeptide, complex, pharmaceutical composition, methods for treating a coagulopathy, to produce a polypeptide comprising a modified vwf, and to increase vwf factor viii binding affinity and factor viii half-life, use of a modified polypeptide or complex, polynucleotide, plasmid or vector, and host cell. |
US10364982B2 (en)* | 2015-11-19 | 2019-07-30 | Ansaldo Energia Switzerland AG | Method for reconditioning fuel nozzle assemblies |
SG11201805494WA (en) | 2016-01-07 | 2018-07-30 | Csl Behring Recombinant Facility Ag | Mutated von willebrand factor |
Publication number | Publication date |
---|---|
JP6851381B6 (en) | 2021-04-21 |
MX2018008337A (en) | 2018-09-17 |
JP6851381B2 (en) | 2021-03-31 |
EP3400002A4 (en) | 2019-07-03 |
AU2017204955A1 (en) | 2018-07-12 |
US10806774B2 (en) | 2020-10-20 |
HK1256525A1 (en) | 2019-09-27 |
EP3400002A1 (en) | 2018-11-14 |
DK3400002T3 (en) | 2022-04-11 |
KR20180094114A (en) | 2018-08-22 |
ES2909573T3 (en) | 2022-05-09 |
BR112018013861A2 (en) | 2018-12-18 |
US20190015483A1 (en) | 2019-01-17 |
CN108472338A (en) | 2018-08-31 |
EP3400002B1 (en) | 2022-02-02 |
CN108472338B (en) | 2022-12-30 |
SG10201912498YA (en) | 2020-02-27 |
JP2019507587A (en) | 2019-03-22 |
AU2017204955B2 (en) | 2021-04-01 |
RU2018128582A (en) | 2020-02-11 |
CA3010720A1 (en) | 2017-07-13 |
WO2017117631A1 (en) | 2017-07-13 |
Publication | Publication Date | Title |
---|---|---|
SG11201805497QA (en) | Mutated truncated von willebrand factor | |
SG11201805494WA (en) | Mutated von willebrand factor | |
SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201803848YA (en) | Fluxed deasphalter rock fuel oil blend component oils | |
SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
SG11201907855QA (en) | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
SG11201907209QA (en) | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof | |
SG11201806398YA (en) | Optimized factor viii genes | |
SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
SG11201804674UA (en) | Heteroarylhydroxypyrimidinones as agonists of the apj receptor | |
SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
SG11201804589TA (en) | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | |
SG11201809764XA (en) | Humanized anti-il-1r3 antibodies | |
SG11201810853UA (en) | Anti-tnfrsf25 antibodies | |
SG11201804704PA (en) | Compositions and methods for decreasing tau expression |